drugset / Trial / NCT06362096
A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer
NaSingle-groupOpen-labelPrevention
Summary
To explore a reasonable and effective way to reduce the incidence of grade 3 or above diarrhea caused by pyrotinib
Timeline
- Start
- 2024-05
- Primary completion
- 2025-05
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyrotinib | Small molecule | 400 mg | Oral |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |